IMMG.US Immage Biotherapeutics Corp
- Market cap
- USD 15.2K
- P/E
- -
- P/B
- 0.68x
- ROE
- -15,351.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Feb 2017.
Is IMMG.US undervalued?
Graham numberThe Graham number of Immage Biotherapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immage Biotherapeutics Corp fundamental analysis
No fundamental analysis for Immage Biotherapeutics Corp yet.
Immage Biotherapeutics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immage Biotherapeutics Corp
Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015. The company was founded in 2012 and is headquartered in Bethesda, Maryland. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited.
Full company profileImmage Biotherapeutics Corp financial statements
2017 annualized: Fiscal year 2017 is not finished. Income statement and cash flow are annualized from 2 quarters up to Feb 28, 2017, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immage Biotherapeutics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -12.0K | -18.6K | -58.8K | -216K | -3.43M |
| Net Income | -12.0K | -18.6K | -58.8K | -216K | -3.43M |
| Balance Sheet | |||||
| Total Assets | 7.22K | 2.34K | 80.2K | 243K | 90.8K |
| Total Liabilities | 16.1K | 24.0K | 51.4K | 55.8K | 68.5K |
| Shareholders' Equity | -8.93K | -21.6K | 28.8K | 187K | 22.3K |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||||
| Operating Cash Flow | -11.9K | -17.6K | -57.1K | -216K | -286K |
| Capital Expenditure | 44.8K | 44.8K | 44.8K | 0.00 | 0.00 |
| Ratios | |||||
| ROE | - | - | -204.3% | -115.6% | -15,351.1% |
| ROA | -166.5% | -792.3% | -73.3% | -89.0% | -3,776.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Immage Biotherapeutics Corp dividends
Immage Biotherapeutics Corp has not paid dividends in the last 4 fiscal years.
Last stock split: 273:1 on Feb 13, 2015.
Who owns Immage Biotherapeutics Corp
- Insiders 69.86%
- Institutions 0.00%
- Public & others 30.14%
- Shares outstanding 152M
- Free float 45.7M
Immage Biotherapeutics Corp company profile
- Company name
- Immage Biotherapeutics Corp
- Ticker
- IMMG.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- August
- Address
- 10411 Motor City Drive, Bethesda, MD, United States, 20817
- Phone
- 866 692 2939
- Website
- immagebio.com
About Immage Biotherapeutics Corp
Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015. The company was founded in 2012 and is headquartered in Bethesda, Maryland. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited.
Immage Biotherapeutics Corp management
3- Mr. Zhi Cong MouChief Executive Officer, President, Treasurer, Secretary and Director · born 1983
- Mr. Elton F. Norman CPA, Esq., J.D.Chief Financial Officer and Director · born 1963
- Mr. Mahesh Narayanan M.S.COO & Director · born 1989